Cohort 1
The first HiveBio cohort includes ten visionary startups from the greater Philadelphia area, each driving innovation across drug development, regenerative medicine, AI diagnostics, medical prosthetics, and digital health. Selected from a highly competitive pool, these companies stood out for their potential to transform the life sciences landscape.
The Companies
Ajaya Bio
Developing BOLT-360™, a bispecific platform enhancing specificity, safety, and access to previously untargetable pathways in autoimmune diseases and oncology.
Innovating biomimetic, cell-friendly scaffolds to enhance ophthalmic tissue replacement and advance corneal treatment.
Creating novel cancer therapies with a robust preclinical program to support future drug development for triple-negative breast cancer.
Medical device start-up pioneering gene therapeutic pathways to support neurological health.
Medical device start-up redefining remote monitoring for cardiovascular disease with mHeart, which enables mobile triage, real-time monitoring, and rapid heart disease diagnostics during episodes of patient chest discomfort.
Rare disease start-up ushering in a new age of functional cures for Friedreich’s ataxia (FA) patients.
Biotech software start-up digitizing “preventive actions”, in-line validation & other quality control operations for laboratory and biomanufacturing equipment.
Drug therapeutic start-up utilizing PARP inhibitor (PARPi) analogues with radiopharmaceutical platforms to support treatments in oncology.
Pioneering innovative biomaterial-based growth factor delivery for treating Stage I & II diabetic foot ulcers.
Pioneering novel technology to provide continuous monitoring of a mother’s risk for postpartum hemorrhage and excessive blood loss after childbirth - the leading causes of maternal deaths globally.
The inaugural cohort of HiveBio’s Virtual Accelerator Program is made possible by the generous support of the John S. and James L. Knight Foundation to enhance funding opportunities and outcomes for underrepresented start-up entrepreneurs in life sciences.